These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16549819)

  • 1. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group.
    Chatal JF; Campion L; Kraeber-Bodéré F; Bardet S; Vuillez JP; Charbonnel B; Rohmer V; Chang CH; Sharkey RM; Goldenberg DM; Barbet J;
    J Clin Oncol; 2006 Apr; 24(11):1705-11. PubMed ID: 16549819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement.
    Salaun PY; Campion L; Bournaud C; Faivre-Chauvet A; Vuillez JP; Taieb D; Ansquer C; Rousseau C; Borson-Chazot F; Bardet S; Oudoux A; Cariou B; Mirallié E; Chang CH; Sharkey RM; Goldenberg DM; Chatal JF; Barbet J; Kraeber-Bodéré F
    J Nucl Med; 2012 Aug; 53(8):1185-92. PubMed ID: 22743249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
    Kraeber-Bodéré F; Rousseau C; Bodet-Milin C; Ferrer L; Faivre-Chauvet A; Campion L; Vuillez JP; Devillers A; Chang CH; Goldenberg DM; Chatal JF; Barbet J
    J Nucl Med; 2006 Feb; 47(2):247-55. PubMed ID: 16455630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft.
    Kraeber-Bodéré F; Faibre-Chauvet A; Saï-Maurel C; Gautherot E; Fiche M; Campion L; Le Boterff J; Barbet J; Chatal JF; Thédrez P
    J Nucl Med; 1999 Jan; 40(1):198-204. PubMed ID: 9935077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections.
    Kraeber-Bodéré F; Faivre-Chauvet A; Saï-Maurel C; Campion L; Fiche M; Gautherot E; Le Boterff J; Barbet J; Chatal JF; Thédrez P
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3183s-3189s. PubMed ID: 10541362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pretargeted radioimmunotherapy (pRAIT) in medullary thyroid cancer (MTC).
    Kraeber-Bodéré F; Salaun PY; Ansquer C; Drui D; Mirallié E; Faivre-Chauvet A; Barbet J; Goldenberg DM; Chatal JF
    Tumour Biol; 2012 Jun; 33(3):601-6. PubMed ID: 22396039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer.
    Kraeber-Bodéré F; Salaun PY; Oudoux A; Goldenberg DM; Chatal JF; Barbet J
    Cancer; 2010 Feb; 116(4 Suppl):1118-25. PubMed ID: 20127952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR.
    Juweid ME; Hajjar G; Stein R; Sharkey RM; Herskovic T; Swayne LC; Suleiman S; Pereira M; Rubin AD; Goldenberg DM
    J Nucl Med; 2000 Jan; 41(1):93-103. PubMed ID: 10647610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ¹⁸F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma.
    Salaun PY; Campion L; Ansquer C; Frampas E; Mathieu C; Robin P; Bournaud C; Vuillez JP; Taieb D; Rousseau C; Drui D; Mirallié E; Borson-Chazot F; Goldenberg DM; Chatal JF; Barbet J; Kraeber-Bodéré F
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1501-10. PubMed ID: 24806110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
    Kraeber-Bodéré F; Faivre-Chauvet A; Ferrer L; Vuillez JP; Brard PY; Rousseau C; Resche I; Devillers A; Laffont S; Bardiès M; Chang K; Sharkey RM; Goldenberg DM; Chatal JF; Barbet J
    Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3973S-81S. PubMed ID: 14506196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial.
    Kraeber-Bodéré F; Bardet S; Hoefnagel CA; Vieira MR; Vuillez JP; Murat A; Ferreira TC; Bardiès M; Ferrer L; Resche I; Gautherot E; Rouvier E; Barbet J; Chatal JF
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3190s-3198s. PubMed ID: 10541363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretargeted anti-carcinoembryonic-antigen radioimmunotherapy for medullary thyroid carcinoma.
    Machens A; Dralle H
    J Clin Oncol; 2006 Jul; 24(20):e37; author reply e38. PubMed ID: 16829644
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunohistology of carcinoembryonic antigen (CEA)-expressing tumors grafted in nude mice after radioimmunotherapy with 131I-labeled bivalent hapten and anti-CEA x antihapten bispecific antibody.
    Gautherot E; Kraeber-Bodéré F; Daniel L; Fiche M; Rouvier E; Saï-Maurel C; Thedrez P; Chatal JF; Barbet J
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3177s-3182s. PubMed ID: 10541361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretargeting of carcinoembryonic antigen-expressing tumors with a biologically produced bispecific anticarcinoembryonic antigen x anti-indium-labeled diethylenetriaminepentaacetic acid antibody.
    van Schaijk FG; Oosterwijk E; Soede AC; Broekema M; Frielink C; McBride WJ; Goldenberg DM; Corstens FH; Boerman OC
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7130s-7136s. PubMed ID: 16203812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medullary thyroid carcinoma surgical cytoreduction induces an increase in serum calcitonin and carcinoembryonic antigen doubling times.
    Papapetrou PD; Polymeris A
    Exp Clin Endocrinol Diabetes; 2012 Mar; 120(3):164-8. PubMed ID: 22328112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial.
    Vuillez JP; Kraeber-Bodéré F; Moro D; Bardiès M; Douillard JY; Gautherot E; Rouvier E; Barbet J; Garban F; Moreau P; Chatal JF
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3259s-3267s. PubMed ID: 10541373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcitonin and carcinoembryonic antigen doubling times as prognostic factors in medullary thyroid carcinoma: a structured meta-analysis.
    Meijer JA; le Cessie S; van den Hout WB; Kievit J; Schoones JW; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2010 Apr; 72(4):534-42. PubMed ID: 19563448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medullary thyroid carcinoma: prognosis of familial versus nonfamilial disease and the role of radiotherapy.
    Samaan NA; Schultz PN; Hickey RC
    Horm Metab Res Suppl; 1989; 21():21-5. PubMed ID: 2807151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term prognosis of medullary thyroid carcinoma.
    Rendl G; Manzl M; Hitzl W; Sungler P; Pirich C
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):497-505. PubMed ID: 18331612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.
    Oudoux A; Salaun PY; Bournaud C; Campion L; Ansquer C; Rousseau C; Bardet S; Borson-Chazot F; Vuillez JP; Murat A; Mirallié E; Barbet J; Goldenberg DM; Chatal JF; Kraeber-Bodéré F
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4590-7. PubMed ID: 17878252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.